Lille Cedex

• AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended recruitment
  2024-515479-36-00 5 2023-07-05 Chronic Myeloid Leukemia
• Evaluation of Long-Term Safety and Efficacy of Apitegromab in Patients with Spinal Muscular Atrophy (a genetic condition that causes muscle … Ended recruitment
  2024-511654-42-00 5 2023-06-28 Spinal Muscular Atrophy (SMA)
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin … Ended recruitment
  2023-507522-16-00 5 2023-05-22 Metastatic Esophageal or Gastric Cancer
• A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended recruitment
  2022-502215-10-00 5 2023-05-04 Haemophilia A (with or without inhibitors)
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A clinical trial to investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of A … Ended recruitment
  2023-507052-69-00 4 2023-03-29 Multifocal Motor Neuropathy
• A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended recruitment
  2022-500953-17-00 4 2023-03-23 Moderately to severely active ulcerative colitis
• CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti … Ended recruitment
  2024-514345-11-00 9 2023-03-15 children, adolescents and young adults with Acute Lymphoblastic Leukem
• PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien … Ended recruitment
  2022-501217-31-00 10 2023-03-09 Hepatocellular carcinoma
• An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). Ended recruitment
  2023-510081-27-00 9 2023-02-28 Systemic Lupus Erythematosus.
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• A study of ONCOFID-P-B administered intravesically to patients with Carcinoma in Situ of the bladder who have not responded to the standard … Ended recruitment
  2024-512568-72-00 5 2023-02-24 BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T
• A study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with relapsed/refractory Follicular L … Ended recruitment
  2024-511594-30-00 5 2023-02-23 Relapsed/Refractory Follicular Lymphoma
• Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Ended recruitment
  2024-514004-14-00 3 2023-02-23 Alzheimer’s Disease
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife … Ended recruitment
  2023-503928-10-00 4 2023-02-01 Prodromal and Early Manifest Huntington’s Disease
• EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended recruitment
  2023-504832-16-00 4 2023-01-24 DIFFUSE LARGE B CELL LYMPHOMA
• Impact of a treatment with angiotensin receptor blocker on outcome after acute kidney injury in patients discharged from the ICU “START-or-N … Ended recruitment
  2024-515845-40-00 5 2022-11-22 Acute kidney injury
• A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N … Ended recruitment
  2024-510947-71-00 5 2022-11-21 Chronic Myeloid Leukemia
• Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended recruitment
  2023-508284-77-00 5 2022-11-16 Generalized Myasthenia Gravis with autoantibodies against acetylcholin
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane … Ended recruitment
  2024-516168-27-00 5 2022-11-10 Adult patients with persistent or chronic immune thrombocytopenia
• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide i … Ended recruitment
  2023-509859-13-00 5 2022-11-09 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis

Showing 433–456 of 681 trials